Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
11.54
Nov 20 • 3:59 PM ET Dollar change-0.63 Percentage change(-5.18%)
Aftermarket Close
11.33
Aftermarket • 7:30 PM ET Dollar change-0.21 Percentage change(-1.82%)
Index
-
Market Cap
816.80M
Enterprise Value
741.75M
Income
24.04M
Sales
386.69M
Book/sh
4.11
Cash/sh
2.68
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
-
IPO
Dec 23, 2020
P/E
36.63
Forward P/E
31.68
PEG
0.21
P/S
2.11
P/B
2.80
P/C
4.31
P/FCF
29.16
EV/EBITDA
16.01
EV/Sales
1.92
Quick Ratio
2.65
Current Ratio
3.23
Debt/Eq
0.39
LT Debt/Eq
0.36
Option/Short
No / Yes
EPS (ttm)
0.32
EPS next Y
0.36
EPS next Q
0.10
EPS this Y
781.00%
EPS next Y
3.37%
EPS next 5Y
148.88%
EPS past 3/5Y
-41.84% -41.23%
Sales past 3/5Y
22.40% 12.25%
EPS Y/Y TTM
2242.07%
Sales Y/Y TTM
6.67%
EPS Q/Q
174.95%
Sales Q/Q
21.29%
Insider Own
-
Insider Trans
-
Inst Own
0.11%
Inst Trans
72.94%
ROA
4.95%
ROE
8.65%
ROIC
6.06%
Gross Margin
82.77%
Oper. Margin
8.84%
Profit Margin
6.22%
SMA20
-7.41%
SMA50
4.33%
SMA200
-13.32%
Trades
Shs Outstand
70.78M
Shs Float
-
52W High
21.34 -45.92%
52W Low
9.11 26.67%
Volatility
3.32% 3.93%
ATR (14)
0.54
RSI (14)
45.45
Beta
-0.06
Rel Volume
0.49
Avg Volume
21.32K
Volume
10,517
Perf Week
-8.41%
Perf Month
8.15%
Perf Quarter
0.70%
Perf Half Y
-8.41%
Perf YTD
-34.69%
Perf Year
-28.98%
Perf 3Y
-0.94%
Perf 5Y
33.87%
Perf 10Y
-
Prev Close
12.17
Price
11.54
Change %
-5.18%
Consensus
Strong Buy
Avg. Price Target
$30.60
Implied Upside
+165.2%
Analysts2incl. previous ratings
Rating Distribution2 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Apr 10, 2026Initiated
CCanaccord Genuity
Buy$37+220.6%
Dec 09, 2024Initiated
JEF logoJJefferies
Buy$14+21.3%
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST, Joenja, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.
M.Sc.Mr. Kenneth Lynard EMBA
Co-CEO & Chief Commercial OfficerMs. Leverne Marsh BPHARM
Chief Operations OfficerMs. Mireille Sanders M.Sc.
VP of Investor Relations & Corporate CommunicationsMr. Michael K. Levitan
Chief Legal & Compliance Officer and Company SecretaryMr. Ruud Van Outersterp L.L.M.